GEN Exclusives

More »

GEN News Highlights

More »
May 1, 2007

DiagnoCure Acquires Two Colorectal Cancer Tests from TDT

  • DiagnoCure secured exclusive, worldwide rights to two molecular tests for colorectal cancer from Targeted Diagnostics & Therapeutics (TDT). It also gained the option to a CLIA-certified U.S. service laboratory to commercialize molecular cancer diagnostics tests.

    The two tests for colorectal cancer are based on the detection of guanylyl cyclase C (GCC), a gene that appears normally in cells lining the intestinal track but has only been found outside the intestine when colorectal cancer has metastasized.
    DiagnoCure reports that initial research conducted by Scott A. Waldman, M.D., Ph.D., of Thomas Jefferson University showed GCC to be 95–100% accurate in detecting the spread or recurrence of colon cancer, in lymph nodes or blood.

    While the total value of the transaction will not be disclosed, DiagnoCure's initial payment includes $2.2 million in shares to TDT. It will also pay performance-based milestone and royalties on revenues generated by the tests.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »